In a panel discussion at the TCT conference in Boston and in a recently published report, Jonathan Norris of Silicon Valley Bank explained why health care investment has slowed this year, and why remaining pragmatic and optimistic is important moving forward.
Investment in the life sciences has been very different in 2022 compared to 2021.
Deal volume and value is down, leading some investors and key opinion leaders to say
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.
Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.
NeuroOne is preparing to submit its OneRF Trigeminal Nerve Ablation System to the US FDA for treating trigeminal neuralgia, a chronic facial pain condition. CEO Dave Rosa told Medtech Insight that he expects a possible product launch by fall 2025.
